Group 1 - The company plans to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, totaling approximately 93.46 million yuan, which represents 25.72% of the net profit attributable to shareholders for the first half of 2025 [1][36][37] - The total share capital as of August 8, 2025, is 187,847,422 shares, with 922,051 shares held in the repurchase account excluded from the dividend distribution [1][37] - The company will not issue bonus shares or increase capital from reserves [1][36] Group 2 - The company has appointed KPMG Huazhen as the new auditing firm for the fiscal year 2025, replacing the previous firm, Gongzheng Tianye [4][17] - The change in auditing firms is due to the company's business development, particularly in overseas markets, and the need to ensure the quality of financial statement audits [4][17] - Both the previous and new auditing firms have been informed of the change and have no objections [4][18] Group 3 - As of June 30, 2025, the company has used a total of approximately 1.70 billion yuan of the raised funds, with a remaining balance of about 47 million yuan [24][26] - The company has established a dedicated account for managing raised funds and adheres to strict approval procedures for their use [27][28] - There were no instances of idle raised funds being temporarily used for working capital during the reporting period [29][30] Group 4 - The company’s board of directors and supervisory board have approved the half-year report and the profit distribution plan, which will be submitted for approval at the upcoming shareholder meeting [50][51] - The company has complied with all relevant regulations regarding the management and disclosure of raised funds, ensuring transparency and accountability [52]
南微医学科技股份有限公司2025年半年度报告摘要